Introduction {#Sec1}
============

Connective Tissue Growth factor (CTGF, CCN2) is a secreted 36-38 kDa protein and a prototypical member of the CCN (Cyr61/CTGF/Nov) family of matricellular proteins. Family members have four domains, each of which can bind several ligands. Amongst these are (a) other growth factors (e.g. TGF-β, BMP-4 and -7, IGF-1, VEGF), whose function is then modified; (b) cell surface proteins (e.g. integrins, LRP-1, heparan sulphate proteogycans, tyrosine receptor kinase A), through which intracellular signalling may be initiated; and (c) extracellular matrix proteins (e.g. fibronectin) which may act as a sink for CCN proteins and modify their turnover. With so many potential interactions it is predictable that CCN proteins will influence many different biological events (Leask and Abraham [@CR40]). CTGF is typical in this respect. Many responses triggered by it, or by fragments derived proteolytically from it, have been described since it was discovered in 1991 (Bradham et al. [@CR8], de Winter et al. [@CR17])). However it was recognised early on that CTGF stimulates the production of extracellular proteins by mesenchymal cells and that its expression in such cells is induced by the profibrotic cytokine TGF-β (Frazier et al. [@CR21]), suggesting that it may have an important role in fibrosis.

About 30-40% of diabetics develop diabetic nephropathy (DN). In this life threatening disease, the basement membranes of the glomeruli (filtration units of the kidney) and of the renal tubules draining the urinary filtrate from them become thickened. Later the mesangium, an extracellular matrix which supports the glomerular capillary loops, and the interstitial areas between the tubules become fibrosed (Mason and Wahab [@CR47]). Expanding mesangial fibrosis "crushes" the capillaries compromising filtration, and expanding fibrosis in the interstitium correlates closely with declining renal function (Steffes et al. [@CR61], Gilbert and Cooper [@CR27]). It is widely accepted that these processes are mediated by TGF-β (Sharma and Ziyadeh [@CR60], Border et al. [@CR7]) whose expression is elevated in renal tissues in DN (Yamamoto et al. [@CR77]). Treatment of diabetic mice (db/db) with a neutralising antibody to TGF-β1 attenuated glomerular hypertrophy and prevented increased expression of collagen and fibronectin and glomerular mesangial matrix expansion (Ziyadeh et al. [@CR82]). However CTGF has many of the same profibrotic actions as TGF-β and may act as a mediator of TGF-β actions on mesenchymal cells (Grotendorst [@CR29]). Indeed, treatment with a CTGF- antisense oligonucleotide attenuates progression of diabetic nephropathy in diabetic mice (Guha et al. [@CR32]). Moreover high plasma CTGF levels are an independent predictor of end-stage renal disease and mortality in DN in human Type 1 diabetes (Nguyen et al. [@CR52]). Several publications have proposed that CTGF could be an alternative therapeutic target to TGF-β in DN (e.g. Crean et al. [@CR13], Wahab et al. [@CR67], Blom et al. [@CR6], Twigg and Cooper [@CR65]).

Renal CTGF expression in diabetic nephropathy {#Sec2}
=============================================

Each glomerulus comprises a series of capillary loops, through which blood circulates, and is enclosed by a Bowman's capsule. Its supporting core structure, the mesangium, is composed of mesangial cells surrounded by their extracellular matrix. The capillary lumens are lined with fenestrated endothelial cells sitting on a basement membrane -- the glomerular basement membrane (gbm). Water and small solutes in the blood diffuse across the gbm into the urinary space on the abluminal side, forming the urinary filtrate. This side of the gbm is covered by the foot processes of podocytes, also termed glomerular visceral epithelial cells. The filtrate then passes into the tubular system where molecules are both absorbed from and added to the tubular fluid by the lining epithelial cells, finally forming the urine. The tubules occupy both outer cortical and inner medullary areas of the kidney and are juxtaposed to intertubular blood vessels and a small amount of interstitium which contains a few fibroblast-like cells. This tubulointerstitium accounts for approximately 90% of kidney volume (Border et al. [@CR7]).

Only low levels of glomerular CTGF are found in normal human glomeruli, but both mRNA and protein levels of the factor increase during the early (incipient) stage of DN and continue to do so as the disease progresses. Both glomerular podocytes and mesangial cells express CTGF in DN (Adler et al. [@CR2], Wahab et al. [@CR69]). Similarly, glomerular CTGF mRNA and protein levels increase in murine models of DN, initially in podocytes and later in parietal epithelia (lining the Bowman's capsule) and mesangial cells (Roestenberg at al. [@CR58]). Distal to the glomerulus, CTGF protein levels are increased in proximal tubular epithelial cells (PTECs) in rodent models of DN in both type 1diabetes (STZ-rats after 30 weeks) and type 2 diabetes (db/db mouse) (Wang et al. [@CR73], Guha et al. [@CR32]). Interestingly, CTGF mRNA expression was induced in mouse PTEC cultures by proximal tubular fluid collected by micropuncture from STZ-diabetic rats (Wang et al. [@CR73]). PTEC's would be exposed to low molecular weight growth factors in the tubular fluid in vivo, such as TGF-β originating in the glomerular ultrafiltrate. CTGF protein was also detected in distal tubules of diabetic rats but controls also stained positively (Wang et al. [@CR73]) so it is not clear whether its level are increased in the disease state. Although it is well established that declining renal function during progressive human DN correlates with interstitial expansion and fibrosis (reviewed by Gilbert and Cooper [@CR27]), few studies have specifically addressed the expression of CTGF in interstitial cells in DN. One reason for this may be because rodent models of DN show little or no interstitial fibrosis even though glomerular changes are well developed. However STZ-diabetic mice show some increase in CTGF mRNA in tubulointerstitial areas and in vessel walls (Roestenberg et al. [@CR58]) and CTGF mRNA expression is elevated in human renal interstitial fibrosis in a variety of kidney diseases, including DN. The interstitial cells over-expressing CTGF were indentified as myofibroblasts by their co-expression of α-smooth muscle actin (Ito et al. [@CR35]).

Increased CTGF expression in renal cells in DN is likely to be induced by several different factors, including the high glucose environment, mechanical strain, TGF-β, Advanced Glycation End Product (AGE) -- proteins and reactive oxygen species (ROS) ((Murphy et al. [@CR50], Riser et al. [@CR57], Wahab et al. [@CR67], Mason and Wahab [@CR47], Burns et al. [@CR10]). AGE-proteins and ROS form in tissues in high glucose conditions and mesangial cells are subject to mechanical strain due to elevated systemic and intraglomerular pressure in diabetes (Forbes et al. [@CR20]). CTGF is also able to auto-induce further CTGF gene expression in mesangial cells (Riser et al. [@CR57]). It should be noted that one group reported a decrease in glomerular CTGF mRNA in DN in type 2 diabetes. This correlated with a decrease in a podocyte specific marker and mRNAs indicating podocyte loss (Baelde et al. [@CR4]). Thus following increases in expression, overall glomerular levels of CTGF mRNA may decrease with increasing podocyte loss.

CTGF and mesangial cells {#Sec3}
========================

CTGF induces many responses in human mesangial cells in vitro which are relevant to the development of glomerulopathy in DN in vivo. It stimulates fibronectin and plasminogen activator inhibitor-1 synthesis, thus contributing to the mesangial extracellular matrix and, potentially, opposing turnover of the matrix since plasminogen activator is an important activator of matrix metalloproteinases (Wahab et al. [@CR67]). CTGF also upregulates expression of α5β1 integrin, a plasma membrane anchor to which fibronectin must attach to permit the formation of an extracellular fibronectin fibrillar network. Increased levels of ligand-occupied β1 integrin appear on the cell surface in cells treated with CTGF for 48 h, promoting both increased cell adhesion and mesangial matrix expansion (Weston et al. [@CR74]). However over short periods (12 h) CTGF induced dissolution of mesangial cell focal adhesions and a transient disassembly of the actin cytoskeleton, which reformed after 24 h. In vitro, these cytoskeletal changes may facilitate increased mesangial cell migration which was maximal after 4 h of CTGF treatment (Crean et al. [@CR14]). Interestingly mesangial cell migration in response to CTGF was abrogated in a high glucose (30 mM) environment. Migration requires activation of PKCζ and CTGF was unable to stimulate further increases in phosphorylation of PKCζ which was already highly phosphorylated after exposure to high glucose. Other CTGF responses remained intact in high glucose (Furlong et al. [@CR22]). These results illustrate that some CTGF-induced cell responses are likely to be time and context dependent.

CTGF induces mesangial cell cycle arrest in late G1 phase. This occurs by induction of Cyclin D1, which initiates the G1 phase, and by stimulating the expression of the cyclin-dependent kinase inhibitors p15 ^INK4^, p21^Cip1^ and p27^Kip1^ which bring about arrest in late G1. This arrest is accompanied by mesangial cell hypertrophy as the cells continue to synthesize proteins at a high level (Wahab et al. [@CR68]). Furthermore, CTGF blocks mesangial cell death by inducing MAP kinase phosphatase-1(MKP-1), which prevents MAPK p38 phosphorylation and apoptosis (Wahab et al. [@CR72]). Persistence of myofibroblast-like cells producing high levels of extracellular matrix proteins is one of the hallmarks of fibrosis, in contrast to apotosis of such cells in damaged tissue undergoing normal wound healing and repair. TGF-β also induces these changes in mesangial cells. However such TGF-β-induced effects are blocked by treating the cells with a CTGF-antisense oligonucleotide, or CTGF-siRNA. Since mesangial matrix expansion, mesangial cell hypertrophy, and prolonged cell survival, all occur in the mesangium in DN, it is likely that TGF-β plays a key role in orchestrating these events in the disease, but that CTGF facilitates its actions (Wahab et al. [@CR72]), as discussed below.

CTGF and podocytes {#Sec4}
==================

The earliest sign of onset of DN is microalbuminuria. Glomerular permeability to plasma proteins increases progressively as the disease advances and persistent proteinuria may contribute to tubular damage further along the nephron (Strutz [@CR62]). The change in permeability is due predominantly to podocyte injury and loss, and to changes in the slit diaphragms, regions of special protein composition between adjacent gbm attachment sites of podocyte foot processes (Wolf et al. [@CR75], Li et al. [@CR41]). Recent studies of STZ-induced diabetes in mice which are transgenic for specific expression of CTGF in podocytes point to an important role for CTGF in microalbuminuria. After 12 weeks of diabetes CTGF protein levels were higher in podocytes of transgenic mice than in non-transgenic mice and urinary albumin excretion was enhanced significantly in the former compared to the latter. The increased albuminuria may relate to podocyte injury in the diabetic transgenics since their podocytes were vacuolated, reduced in number, and levels of podocin, a protein known to be critical for slit diaphragm function, were partly reduced (Yokoi et al. [@CR80]). The biochemical mechanism underlying the link between podocyte CTGF expression and microalbuminuria is currently unknown. However it is noteworthy that whilst treatment of diabetic mice (db/db) with an anti-TGF-β antibody prevented increased kidney matrix protein expression and mesangial expansion, it did not reduce albuminuria (Ziyadeh et al. [@CR82]), raising the possibility that CTGF may have a TGF-β-independent role in the latter. In agreement with this notion, CTGF antisense oligonucleotide treatment of db/db mice or STZ-induced diabetic mice did attenuate albuminuria (Guha et al. [@CR32]).

Podocyte-specific CTGF-transgenic mice have two other interesting characteristics. First, endogenous glomerular CTGF mRNA levels are also enhanced in diabetic transgenic mice, but mainly in the mesangial area, suggesting induction of mesangial cell CTGF expression by transgenic--CTGF from podocytes. Thus CTGF expressed by one cell type may have paracrine effects on CTGF expression in another cell type. It was proposed that the enhanced mesangial expansion seen in these diabetic transgenics may be due to decreased glomerular MMP2 expression/activity and therefore decreased matrix degradation, rather than to enhanced matrix synthesis (Yokoi et al. [@CR80]). Second, non-diabetic transgenic mice had normal renal histology even though their glomerular CTGF protein levels were five times higher than in non-transgenic mice. Thus either CTGF levels can vary widely without affecting tissues or, more likely, CTGF acts on some cells in concert with one or more other factors, for example TGF-β, and has no effect if such factors are absent.

CTGF and the tubulointerstitium {#Sec5}
===============================

Tubular basement membrane thickening, like gbm thickening (Osterby [@CR54]), occurs early in type1 diabetes. At a later stage tubular atrophy and loss may occur and the interstitium becomes fibrotic and greatly expanded (Fioretto and Maur [@CR19]). This is due to excessive deposition of extracellular matrix by myofibroblastic type cells, probably accompanied by decreased matrix degradation. The underlying mechanisms of renal interstitial fibrosis have similarities in the different kidney diseases in which it develops (Nangaku [@CR51]).

Tubular epithelial cells synthesize the matrix proteins of the tubular basement membrane. Proximal tubular epithelial cells not only express CTGF in DN but are also likely to be exposed to CTGF from the glomerulus. Small proteins like CTGF may filter across the gbm and be present in the tubular fluid in pharmacologically active concentrations (see Wang et al. [@CR73] for example). Mouse PTEC cultures treated with rCTGF increased expression of fibronectin mRNA, but not that of Collagen IIIα1 or collagen1α2 chains (Wang et al. [@CR73]). This may be relevant to the mechanism of basement membrane thickening since fibronectin is a tbm component (Brees et al. [@CR9]) whilst the collagens are components of the interstitial matrix. CTGF may also play a role in early gbm thickening in DN (Thompson et al. [@CR64]).

Potentially, CTGF secreted by PTECs has important paracrine actions on renal interstitial fibroblasts in DN. rCTGF synergised with IGF-1 action on normal renal fibroblasts (NRK-49F cells), stimulating upregulation of collagen IIIα1 mRNA. IGF-1 alone had only a modest stimulatory action whilst CTGF alone had no effect (Wang et al. [@CR73]). CTGF module 1 has a binding site for IGF-1 which is likely to be important in this synergistic action. Moreover Lam et al. ([@CR38]) showed that human renal interstitial fibroblasts synthesize both IGF-1 and CTGF and that their expression increased in hyperglycaemic conditions. This study also recorded that CTGF alone had no effect on collagen types I and III secretion by these cells but it enhanced that induced by IGF-1. It was also reported that an anti-CTGF neutralizing antibody reduced high glucose-induced secretion of types I and III collagen by the fibroblasts, indicating the importance of CTGF in interstitial matrix production by these cells in diabetic conditions. It seems probable that CTGF secreted into the interstitium by PTECs would contribute to this effect on fibroblasts.

Co-culture experiments of murine interstitial fibroblast monolayers with murine PTECs grown on cell culture inserts were used to directly test the paracrine effect of the latter. The inserts allow diffusion of PTEC-secreted products into the fibroblast culture. When fibroblasts alone were stimulated with low doses of TGF-β there was a modest increase in mRNA levels of proteins involved in fibrosis, namely collagen I α1, fibronectin (EIIIA form), PAI-1 and TIMP-1. However in the presence of both TGF-β and PTECs these fibroblast mRNA levels were greatly enhanced. The enhancement was blocked in the presence of a neutralizing anti-CTGF antibody (Okada et al. [@CR55]). Since rCTGF stimulated increases in the same mRNA's in the fibroblast cultures, the enhanced mRNA levels in the co-culture experiments could be due to either an additive effect from the PTEC CTGF, or to this CTGF promoting the effects of TGF-β (see below), or to both actions. Irrespective of this, the results demonstrate a paracrine action of epithelial cell CTGF on interstitial fibroblasts.

The origin of the myofibroblasts which lay down excessive extracellular matrix in interstitial fibrosis in DN and other renal diseases is not well understood. Some may derive from the small number of endogenous interstitial fibroblasts in normal kidneys which become activated by exogenous factors such as TGF-β, CTGF, and FGF-2, secreted by infiltrating inflammatory cells in disease (Strutz [@CR62]). Normal rat kidney fibroblasts (NRK clone 49F) proliferate and differentiate to myofibroblasts (α-SMA positive and incorporate 3H-proline into collagen) in response to CTGF. The proliferative activity resides in the C-terminal domain of CTGF whilst the myofibroblast differentiation activity is in the N-terminal domain (Grotendorst and Duncan [@CR30]). Interestingly another group reported that TGF-β induced proliferation and differentiation of NRK-49F cells to myofibroblasts and that this effect was greatly enhanced if CTGF was present. In these experiments CTGF alone had no effect (Yang et al. [@CR78]). However Gao et al. ([@CR26]) reported that primary cultures of rat renal cortical fibroblasts also proliferate and up-regulate their collagen and fibronectin expression in response to CTGF alone.

Renal interstitial myofibroblasts may also arise from other cell types such as tubular epithelial cells, bone marrow stem cells, vascular pericytes and endothelial cells. In one study unilateral ureteric obstruction (UUO) was used to induce rapid renal interstitial fibrosis in transgenic reporter mice and bone marrow chimeras. 10 days after UUO 36% of interstitial fibroblasts (identified by FSP1 expression) were estimated to arise from tubular epithelial cells (tagged with lacZ expression) and15% from bone marrow cells (tagged with GFP expression), the latter being only 3% more than proportionately found in the contralateral unobstructed kidney (Iwano et al. [@CR36]). Both AGE-albumin and TGF-β induced CTGF expression and EMT in a renal epithelial cell line (NRK-52E) in vitro. Partial knock down of CTGF with siRNA attenuated the induction of EMT by AGE or TGF-β in these cells (Burns et al. [@CR10]). In contrast to EMT, a recent report focuses attention on vascular pericytes as a major source of myofibroblasts in the UUO model. Myofibroblasts were indentified by *coll1a1*-GFP expression (Lin et al. [@CR44]). Interestingly AGE-protein induces CTGF (CCN2) and Cyr 61 (CCN1) expression in retinal pericytes and adenoviral mediated over-expression of both proteins in these cells induced de-adhesion, an event that was followed by apoptosis (Liu et al. [@CR46]).The effect of CTGF on interstitial blood vessel pericytes is not known currently. However the larger interstitial blood vessels remain in human DN and could provide a source of pericytes, even though the number of small peritubular vessels is reduced (Lindenmeyer et al. [@CR45]). A further recent study indicates that endothelial to mesenchymal transition (EndMT) may also contribute interstitial myofibroblasts in interstitial fibrosis. UUO was performed in *Tie2-Cre;R26R-stop-EYFP* mice in which cells of endothelial lineage are labelled with YFP. Substantial numbers of interstitial cells which were FSP1^+^ or α-SMA^+^ also co-expressed YFP(Zeisberg et al. [@CR81]). Similarly 30-50% of cells which stained positive for these mesenchymal cell markers in either murine DN (STZ- induced in CD1 mice), or in Col4a3 knockout mice which develop interstitial fibrosis, also co-expressed the endothelial marker CD31 (Zeisberg et al. [@CR81]). Whilst concerns remain that rodent models of interstitial fibrosis may not precisely mirror that in humans, overall these experiments point to remarkable plasticity of several cell types in the tubulointerstitium in renal disease. The exact role of CTGF in the transition of these various cell types to myofibroblasts remains poorly defined. Nevertheless it is noteworthy that CTGF-antisense oligonucleotide treatment dramatically attenuated the development of myofibroblasts and renal interstitial fibrosis in both the rat UUO model (Yokoi et al [@CR79]).and in the remnant kidney following 5/6 nephrectomy in TGF-β transgenic mice (Okada et al [@CR55]), indicating a key function for the factor in the pathogenic mechanism.

How does CTGF work? {#Sec6}
===================

It seems likely that CTGF exerts its effects on cells in several ways including (i) interaction via one of its domains with other bioactive proteins, modifying the latter's action, (ii) interaction with one or more cell surface tyrosine kinase receptors, triggering intracellular signalling and downstream actions, (iii) interaction with cell surface integrins triggering intracellular signalling and downstream actions, (iv) inducing expression of other secreted molecules with biological actions such as chemokines. There is currently little information about whether one, or another, of these actions is relatively more important than others in DN, or in other disease or biological processes and more than one route of action may be operative in any particular response to CTGF. For example, CTGF promotes many profibrotic effects of TGF-β. It seems to do this by enhancing TGF-β-Smad2/3 signalling by several mechanisms. One mechanism may involve CTGF binding directly to TGF-β, facilitating the latter's interaction with its receptors (Abreu et al [@CR1]). Another mechanism, operative in mesangial cells, is by CTGF binding to the tyrosine receptor kinase complex TrkA/p75 ^NTR^. This triggers intracellular signalling which results in the expression of TIEG-1(TGF-β immediate early gene-1), a known repressor of Smad7 transcription. The latter is a negative regulator of TGF-β signalling (Wahab et al [@CR71], [@CR70]). Thus this results in enhanced transcription of TGF-β responsive genes including those encoding extracellular matrix proteins, which could be important in mesangial expansion in DN. A third potential mechanism involves BMP-7, a factor which counteracts TGF-β -- mediated fibrosis (Patel and Dressler [@CR56]). Nguyen et al ([@CR53]) showed that CTGF binds to BMP-7 with high affinity. Moreover renal cortical levels of CTGF were much higher in STZ-induced DN in CTGF ^+/+^ mice than in CTGF^+/-^ mice and DN changes were attenuated in the latter (Nguyen et al [@CR53]). Higher levels of CTGF were shown to inhibit BMP-7 signalling activity through the Smad1/5 pathway. Normally Smad5 signalling up-regulates Smad6, which in turn blocks phospho-Smad2/3 translocation to the nucleus, reducing TGF-β signalling (Patel and Dressler [@CR56]). Thus with higher CTGF levels this would not occur, promoting TGF-β --phospho-smad2/3 signalling.

CTGF binds other growth factors including BMP-4, whose actions it antagonises by preventing BMP-4 - receptor interaction (Abreu et al [@CR1]). Effects of another interaction, that between CTGF and IGF-1, were discussed above. CTGF also binds VEGF~165~, one of the commonly expressed splice variants of VEGF-A, interrupting its interaction with its receptor VEGFR2 and inhibiting angiogenesis (Inoki et al [@CR34]). VEGF-A is expressed in podocytes and has autocrine actions on them. Its expression is increased in both STZ-diabetic rats and db/db mice and this promotes increased glomerular permeability since proteinuria was reduced by 50% or more by treatment with neutralizing anti-VEGF antibodies (reviewed by Wolf et al [@CR75]). Interactions might conceivably occur between podocyte-derived CTGF and VEGF in early DN, perhaps opposing VEGF-driven increases in glomerular protein permeability. The autocrine VEGF-A - VEGFR2 loop also protects podocytes from apoptosis (Guan at al [@CR31]) so the balance between podocyte derived VEGF-A and CTGF levels and the degree of interaction between the two factors is, potentially, also important in determining podocyte survival in DN. In contrast to rodent studies, glomerular levels of both VEGF-A and CTGF decreased in human DN which was attributed to podocyte loss (Baelde et al 2008). These results may reflect the much later time in the human disease when measurements were made.

CTGF and other members of the CCN family bind to a variety of integrins expressed by different cells, for example integrin αvβ3 on endothelial cells (Babic et al [@CR3]), αIIbβ3 on activated platelets (Jedsadayanmata et al [@CR37]), α6β1 on skin fibroblasts (Chen et al [@CR11]), αvβ3 on hepatic stellate cells (Gao and Brigstock [@CR24]), α5β1 on pancreatic stellate cells (Gao and Brigstock [@CR25]) and α6β1 on gingival fibroblasts (Heng et al [@CR33]). In doing so they activate focal adhesion kinase (FAK) and other intracellular signalling molecules (Chen et al [@CR11]) and initiate a variety of biological responses, including cell adhesion, migration, changes in filopodia and lamellipodia, and extracellular matrix protein deposition. Frequently such responses depend on simultaneous binding of a heparan suphate proteoglycan co-receptor. CTGF signalling via integrin receptors clearly has a role in mesangial cells which may be relevant to the changes in DN. Crean et al ([@CR14]) reported that CTGF increased fibronectin expression in human mesangial cells in a β~3~ integrin-dependent manner which, via Src activation, stimulates p42/p44MAPK and PI3K activation. Neutralizing antibody to β~3~-integrin, or specific inhibition of MAPK, or of PI3K, all reduced the CTGF-induced fibronectin synthesis. Thus both the MAPK and the PI3K/PKB signalling pathways are required to mediate this effect of CTGF.

CTGF also induced a loss of focal adhesions in mesangial cells, but independently of β~3~ integrin -MAPK/PI3K signalling (Crean et al [@CR14]). Dissolution of focal adhesions is a prerequisite of actin cytoskeletal reorganisation for cell migration. CTGF induces cell migration in vitro by dephosphorylation of focal adhesion kinase and paxillin, loss of Rho A activity, activation of Cdc 42 and phosphorylation of PKCζ and GSK-3β (Crean et al [@CR15]). Mechanisms of mesangial cytoskeletal reorganisation are pertinent to understanding the pathobiology of DN since F-actin reorganisation occurs in these cells in a high glucose environment, mediated by PKCζ, with loss of their contractile response to vasoconstrictors (Dlugosz et al [@CR18]). Moreover mesangial F-actin fibres undergo rearrangement in STZ-diabetic rats (Cortes et al [@CR12]). It was proposed that during dissolution of the focal adhesion complex, FAK and paxillin dephosphorylation may depend on the protein tyrosine phosphatase SHP-2 whose activity was elevated in the CTGF--treated mesangial cells (Crean et al [@CR15]). The TrkA/p75 neurotrophin receptor is expressed in mesangial cells and is activated by CTGF (Wahab et al [@CR71]). Interestingly, when TrkA was activated in PC12 pheochromocytoma cells by its established ligand, NGF, SHP-2 rapidly and transiently associated with it, was itself activated by phosphorylation, and was then found associated with multiple phospho-proteins (Goldsmith and Koizumi [@CR28]). This raises the speculative question as to whether a TrkA --SHP-2 pathway could also be involved in mediating CTGF- driven dissolution of focal adhesions in mesangial cells. Crean et al ([@CR16]) went on to show how CTGF promotes the depolymerization of F-actin in mesangial cells and proposed that following CTGF interaction with unspecified cell surface receptors, the PI3K-PKB pathway is activated. Again, CTGF-TrkA interaction could be involved since it also activates the PI3K-PKB pathway (Wahab et al [@CR71]). PKB then phosphorylates p27^Kip1^ at ser10 and thr157. As a result p27^Kip1^ translocates from the nucleus to the cytoplasm where it binds to and inactivates RhoA, uncoupling it from the LIM kinase/cofilin system which regulates actin polymerization/depolymerization. This role of p27^Kip1^ is quite separate from its role as a cyclin-dependant kinase inhibitor referred to above in the discussion of CTGF-induced mesangial cell hypertrophy.

Tyrosine receptor kinase A (TrkA) and p75^NTR^ form a dual receptor which transduces nerve growth factor - initiated signals in both neuronal and non- neuronal cells. This receptor is expressed on mesangial cells and, in response to CTGF, TrkA rapidly autophosphorylates several tyrosine residues (490,674/675), triggering association with several effectors and activating several signalling pathways. TrkA/ p75^NTR^ interaction with CTGF was confirmed by cross-linking experiments. Moreover, K252a, a selective inhibitor of TrkA kinase activity (Tapley et al [@CR63]), blocked the rapid phosphorylation of p42/ p44 MAPK (ERK1, 2), JNK, MAPK7 (ERK5) and PKB (Akt) in mesangial cells treated with CTGF, inferring that these signalling kinases and their associated pathways are activated through TrkA (Wahab et al [@CR71]). CTGF exerts its effects through TrkA-initiated signalling pathways in several ways, each of which is blocked by K252a. First, responses such as upregulated expression of the transcription factor TIEG-1 are a direct result of this signalling (Wahab et al [@CR71], [@CR72]). Second, CTGF-enhanced expression of TGF-β responsive genes such as Col III and PAI1 results from a stimulatory effect on the TGFb-Smad signalling pathway. Ligation of TrkA by CTGF initiates MAPK signalling, TIEG-1 expression and transcriptional repression of Smad 7, as discussed above. This increases the levels of phospho-smad2/3 and their nuclear translocation, stimulating transcription of genes having smad binding elements (SBE) in their promoters (Wahab et al [@CR70]). Third, CTGF induces expression of pharmacologically active proteins in mesangial cells such as MCP-1, RANTES and fracktalkine, these chemokines having important roles in leukocyte chemotaxis and trafficking in inflammation (Wu et al [@CR76]). There are emerging views that inflammation and chemokines play important roles in the pathobiology of DN (Mora and Navarro [@CR49]). Thus, overall, ligation of TrkA by CTGF is likely to be of key importance in the development of the disease.

The low density lipoprotein receptor-related protein (LRP)/α~2~ --macroglobulin receptor (α~2~MR) was identified as a CTGF receptor in bone marrow stromal cells (BMS2) following chromatography of solubilized cell membranes on a CTGF-Sepharose affinity column (Segarini et al [@CR59]). The authors confirmed binding of CTGF to this \~620 kDa member of the LDL receptor family by competition studies with known ligands, immunoprecipitation of CTGF-LRP complex with LRP antibodies, and by showing that CTGF could bind LRP^+/+^ and LRP^+/-^ mouse embryonic fibroblast cells, but not LRP^-/-^ cells. However they were unable to detect phosphorylation of LRP in cells treated with CTGF. LRP was also confirmed as a receptor for adhesion of activated hepatic stellate cells to CTGF (Gao and Brigstock [@CR23]). Subsequently Yang et al ([@CR78]) reported that CTGF induced phosphorylation of the cytoplasmic domain of LRP in a renal fibroblast cell line (NRK-49F). Unlike TGF-β, CTGF was unable to stimulate differentiation of these cells to myofibroblasts. However it increased TGF-β-stimulated differentiation, including the level of α-SMA expression (see above). Receptor associated protein (RAP), a known inhibitor of LRP, blocked CTGF-induced phosphorylation of LRP and reduced the increased α-SMA expression seen with co-stimulation with TGF-β and CTGF. These experiments suggest a possible role for CTGF binding to the LRP receptor in interstitial fibrosis in DN. CTGF also binds the Wnt co-receptor LRP-6 in Xenopus embryos and inhibits Wnt signalling (Mercurio et al [@CR48]). The significance of this interaction has not been explored in mammalian renal cells but it is known that high glucose downregulates Wnt signalling in mesangial cells and that this is proapoptotic (Lin et al [@CR43]).

The C-terminal domain (domain 4), and possibly other domains, of CTGF contain a heparin/heparan sulphate binding site which enables it to ligate cell surface heparan sulphate proteoglycans (HSPGs) (Gao and Brigstock [@CR24]). HSPGs act as co-receptors when CTGF binds to receptors such as the αVβ3 integrin, expressed by activated hepatic stellate cells (Gao and Brigstock [@CR24]). This was shown by prior treatment of cells with heparitinase1, an enzyme which specifically degrades the heparan sulphate side chains of HSPG, or by first culturing cells with sodium chlorate, a treatment which interferes with the sulphation of the heparan sulphate chains. In either case the cells were then unable to adhere to CTGF. Binding of CTGF to the LRP receptor is also heparin-dependent (Gao and Brigstock [@CR23]). Current data indicate no structural changes in glomerular cell -associated heparan sulphate in DN (Van den Born et al [@CR66], Lauer et al [@CR39]) so it seems likely that CTGF should be able to interact normally with HSPG co-receptors in DN.

As discussed above CTGF interacts with several different classes of receptor including integrins, TrkA, LRP and HSPGs. One intriguing speculation is that CTGF-TrkA/p75^NTR^ signalling may require ligation of other cell surface proteins following clustering in the plasma membrane. In an analogous situation, oligodendrocye α6β1integrins cluster in lipid rafts containing PDGFα -receptor on binding their ligand, laminin-2. This enables PDGF to generate a signal within the raft, leading to PI3K/Akt activitation and cell survival (Baron et al [@CR5]). Moreover, TrkA translocates to lipid rafts in PC12 cells on binding NGF, forming receptor-associated signalling complexes which result in ERK1/2 activation (Limpert et al [@CR42]).Could it be that CTGF binds to integrins, HSPGs and TrkA/p75^NTR^ receptors in mesangial cell membranes, promoting clustering into lipid rafts to generate intracellular signaling? Blocking the integrin or HSPG interaction may then prevent CTGF signalling via the neurotrophin receptor. Clearly, much further research is needed before we gain a fuller understanding of how CTGF achieves its effects and how we might modulate them therapeutically in disease states such as DN.
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